-$0.68 Earnings Per Share Expected for Pyxis Oncology, Inc. (NASDAQ:PYXS) This Quarter

Analysts forecast that Pyxis Oncology, Inc. (NASDAQ:PYXSGet Rating) will announce ($0.68) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Pyxis Oncology’s earnings. The lowest EPS estimate is ($0.84) and the highest is ($0.51). The company is expected to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Pyxis Oncology will report full-year earnings of ($3.10) per share for the current fiscal year, with EPS estimates ranging from ($3.72) to ($2.43). For the next fiscal year, analysts expect that the company will post earnings of ($3.40) per share, with EPS estimates ranging from ($4.03) to ($2.69). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Pyxis Oncology.

Pyxis Oncology (NASDAQ:PYXSGet Rating) last released its quarterly earnings results on Friday, May 13th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.36).

NASDAQ:PYXS opened at $2.48 on Tuesday. The stock’s fifty day moving average is $3.38 and its 200 day moving average is $7.15. Pyxis Oncology has a fifty-two week low of $1.96 and a fifty-two week high of $19.00.

In related news, Director Mark Chin sold 1,745,761 shares of the firm’s stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $3.05, for a total transaction of $5,324,571.05. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Several large investors have recently made changes to their positions in PYXS. Citigroup Inc. purchased a new position in shares of Pyxis Oncology in the fourth quarter worth about $35,000. California State Teachers Retirement System purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $64,000. New York State Common Retirement Fund purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $69,000. Davidson Kempner Capital Management LP purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $109,000. Finally, Sandia Investment Management LP purchased a new position in Pyxis Oncology during the fourth quarter valued at approximately $110,000. Hedge funds and other institutional investors own 61.30% of the company’s stock.

Pyxis Oncology Company Profile (Get Rating)

Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.

See Also

Get a free copy of the Zacks research report on Pyxis Oncology (PYXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pyxis Oncology (NASDAQ:PYXS)

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.